Browse

France's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.

The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.